• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PCT
Click for more information
0.79% $1.26

Precinct Prop NZ Ltd & Invest Ltd Stapled Security (NS) - News & Media

watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No News & Media currently available.

(20min delay)
Last
$1.26 		Change
-0.010(0.79%) 		Mkt cap ! n/a
Open High Low Value Volume
$1.27 $1.28 $1.26 $1.672M 1.325M

Buyers (Bids)

No. Vol. Price($)
0 54300 $1.24
 

Sellers (Offers)

Price($) Vol. No.
$1.32 15795 0
Last trade - 10.59am 02/10/2024 (20 minute delay) ?
PCT (NZSX) Chart

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.